With MPM Capital, Sofinnova Partners, Wellington Partners and Merck Ventures was able iOmx Therapeutics AG out of Martinsried Convince four top investors to invest in a Series A round and raise a record-breaking €40 million.
iOmx Therapeutics AG was founded by scientists who previously worked in German Cancer Research Center (DKFZ) in Heidelberg. The startup specializes in drugs designed to prevent cancer from evading the body's immune system. Speaking to the journal Itranskript published by Biocom Verlag, iOmx CEO Sebastian Meier-Ewer expressed his conviction that they can significantly increase the number of patients who respond to cancer immunotherapies.
“Exceptional management, world-class science and a transformative technology platform”
Henrijette Richter, Partner at Sofinnova Partners and Chair of the iOmx Supervisory Board, explains:
“The company combines all the core attributes we were looking for: exceptional management, world-class science, and a transformative technology platform with the potential to deliver proprietary, more effective cancer therapeutics.”
Ruth Herzog, Head of Technology Transfer at the DKFZ, adds:
“For a young company in the life science sector, funding of this amount is a real honor,”
and is happy,
“that intellectual property from the German Cancer Research Center is receiving such recognition from international investors.”
